Cargando…
Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series
We recently reported that neoadjuvant 5-FU, epirubicin, and cyclophosphamide (FEC) followed by weekly paclitaxel and/or trastuzumab induced a high pathological complete response (pCR) rate in hormone-negative patients. The present study examined the therapeutic efficacy of neoadjuvant FEC followed b...
Autores principales: | Kiba, Takayoshi, Morii, Nao, Takahashi, Hirotoshi, Ozaki, Shinji, Atsumi, Misao, Masumoto, Fumi, Yamashiro, Hiroyasu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559240/ https://www.ncbi.nlm.nih.gov/pubmed/26357489 http://dx.doi.org/10.2147/BCTT.S90975 |
Ejemplares similares
-
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer
por: Ishiguro, Hiroshi, et al.
Publicado: (2020) -
Managing the toxicities of the FEC-100 followed by docetaxel regimen: The price of success
por: Laing, Kara
Publicado: (2008) -
FEC91 migration FEC vers DSC
por: Serre, C
Publicado: (1990) -
FEC91 Migration FEC vers DSC
por: Serre, C
Publicado: (1990) -
FEC91 Migration FEC vers DSC
por: Serre, C
Publicado: (1990)